Both Berinert and Cinryze are well‐established therapeutics for HAE, but new pdC1INH therapies are also in clinical development with OCTA‐C1‐INH (Octapharma) in Phase 3 trials [58, 89, 92, 96, 101, 104, 125, 126]. This evidence concerns the gene SERPING1 and hereditary angioedema.